Abrocitinib or Cibinqo (its brand name) targets moderate-to-severe eczema and is meant for patients whose condition is not adequately controlled using topical medications.

Eczema sufferers often experience skin inflammation that leads to itchy patches of skin with flaking, cracking, swelling, oozing, crusting, dryness, pain and sensitivity. (Photo: iStock/Thai Liang Lim)

New: You can now listen to articles.

Sorry, the audio is unavailable right now. Please try again later.

This audio is AI-generated.